Research Topics
Genomes and GenesSpecies | Joshua EpsteinSummaryAffiliation: University of Arkansas for Medical Sciences Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS)Huixiao Hong
Division of Bioinformatics, Z tech at FDA s National Center for Toxicological Research, Jefferson, Arkansas 72079, USA
BMC Bioinformatics 6:S5. 2005..The use of SELDI data for biomarker identification requires application of rigorous procedures to detect and discard low quality spectra prior to data analysis...
Myeloma and bone disease: "the dangerous tango"Joshua Epstein
Myeloma Institute for Research and Therapy, University of Arkansas Medical Sciences College of Medicine, Little Rock, AR 72205, USA
Clin Adv Hematol Oncol 4:300-6. 2006..New approaches to enhance osteoblast activity while controlling osteoclast activity currently under investigation may prove effective in controlling lytic bone disease and myeloma progression...- Consequences of interactions between the bone marrow stroma and myelomaJoshua Epstein
Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Hematol J 4:310-4. 2003.... - Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:176-85. 2007..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients... - Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 115:61-70. 2010..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib... - Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myelomaYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:196-207. 2008.... - Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3122-5. 2008..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382... - Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3115-21. 2008..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well... - Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 136:393-9. 2007..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM... - Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse modelShmuel Yaccoby
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
Haematologica 91:192-9. 2006..Whereas those studies focused on the critical role of myeloma-induced osteoclastogenesis in disease progression, little is known about the impact of osteoblasts and increased bone formation on MM... - The molecular classification of multiple myelomaFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 108:2020-8. 2006..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature... - F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel
Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:2068-76. 2009..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy... 
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 147:347-51. 2009..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent...- The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
Best Pract Res Clin Haematol 20:761-81. 2007.... - Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker
Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 25:1121-8. 2007..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)... - The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsSimona Colla
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 109:4470-7. 2007..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression... - Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 119:e148-50. 2012..The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis... - Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 113:355-9. 2008..Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma... - Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 137:530-6. 2007.... - An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 119:503-12. 2012.... - Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
Blood 118:3512-24. 2011..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels... - Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myelomaYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Br J Haematol 148:726-38. 2010.... - Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survivalYun Ge
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 133:83-92. 2006..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma... - Cancer and the microenvironment: myeloma-osteoclast interactions as a modelShmuel Yaccoby
Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
Cancer Res 64:2016-23. 2004..These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression... - Antimyeloma efficacy of thalidomide in the SCID-hu modelShmuel Yaccoby
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 100:4162-8. 2002.... - Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Clin Cancer Res 18:5499-506. 2012.... - Heparanase promotes the spontaneous metastasis of myeloma cells to boneYang Yang
Department of Pathology, Myeloma Institute for Research and Therapy, Center for Orthopaedic Research, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 105:1303-9. 2005..These studies describe a novel experimental animal model for examining the spontaneous metastasis of bone-homing tumors and indicate that heparanase is a critical determinant of myeloma dissemination and growth in vivo... - Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Stem Cells 29:263-73. 2011..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis... - Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataSarah Waheed
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Haematologica 98:71-8. 2013..Clinicaltrials.gov identifier: NCT00081939)... - A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2276-84. 2007..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions... - Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 135:158-64. 2006..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma... - Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie
Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 107:2633-8. 2006..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma... - The SCID-hu myeloma modelJoshua Epstein
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Science, Little Rock, AK, USA
Methods Mol Med 113:183-90. 2005..This chapter describes in detail all the steps necessary to establish this model and evaluate its success... - Proteasome inhibitors and bone diseaseYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 49:243-8. 2012..This review will discuss the function of PIs in stimulating bone formation and suppression of bone resorption, and the mechanism underlying this process that leads to inhibition bone disease in MM patients... - Beta(2)-microglobulin as a negative growth regulator of myeloma cellsRui Min
Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Br J Haematol 118:495-505. 2002.... - Soluble syndecan-1 promotes growth of myeloma tumors in vivoYang Yang
Arkansas Cancer Research Center, Department of Pathology, and the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 100:610-7. 2002..Thus, high levels of soluble syndecan-1 present in patients with myeloma may contribute directly to the growth and dissemination of the malignant cells and thus to poor prognosis... - Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 116:278-90. 2002..Breaking this loop may help control myeloma... - Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003.... - Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning toolsSudeepa Bhattacharyya
Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Dis Markers 22:245-55. 2006.... - IRF4 addiction in multiple myelomaArthur L Shaffer
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nature 454:226-31. 2008..Although IRF4 is not genetically altered in most myelomas, they are nonetheless addicted to an aberrant IRF4 regulatory network that fuses the gene expression programmes of normal plasma cells and activated B cells... - Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:1587-94. 2007..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM... - The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Blood 110:2041-8. 2007.... - High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee
Blood 110:827-32. 2007..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival... - Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 13:7073-9. 2007..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma... - Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38Jin Xie
Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, Little Rock 72205, USA
J Immunol 171:4792-800. 2003..Thus, our study reveals that LPS has dual effects on DCs that are biologically important: activating existing DCs to initiate an immune response, and inhibiting the generation of new DCs to limit such a response... - Biocompatible nanofiber scaffolds on metal for controlled release and cell colonizationWenjun Dong
Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, USA
Nanomedicine 2:248-52. 2006..The nanofibers can self-organize into macroporous (mostly 0.5-10 microm in diameter) scaffolds potentially useful for developing new bioscaffolds, photocatalysts, sensors, and drug delivery vehicles... - Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturersMichael B Nichol
Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90033, USA
J Manag Care Pharm 13:360-71. 2007..The Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions was intended as a tool to assist health care providers in evaluating and selecting drug products...
Research Grants
- Osteoblasts and their mesenchymal progenitors in myelomaJoshua Epstein; Fiscal Year: 2010....
- Osteoblasts and their mesenchymal progenitors in myelomaJoshua Epstein; Fiscal Year: 2007....
- Osteoblasts and their mesenchymal progenitors in myelomaJoshua Epstein; Fiscal Year: 2009....